Inovio Pharma (INO) Posts Narrower than Expected Q1 Loss
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $1.11 -0.89%
EPS Growth %: +60.7%
Financial Fact:
Grant and miscellaneous revenue: 9.41M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +60.7%
Financial Fact:
Grant and miscellaneous revenue: 9.41M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Inovio Pharmaceuticals, Inc. (NYSE: INO) reported Q1 EPS of ($0.02), $0.02 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $2.7 million versus the consensus estimate of $1.74 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- La-Z-Boy (LZB) Tops Q4 EPS by 44c, Beats on Revenue
- Vince Holding (VNCE) Tops Q1 EPS by 21c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
